Robert F. Williamson, III is currently President and CEO of BioTheryX. Prior to joining BioTheryX, Mr. Williamson served as Chief Executive Officer of both PharmAkea and ATXCo, oncology and fibrosis drug development companies financed through a partnership with Celgene, through PharmAkea’s acquisition by Galecto and ATXCo acquisition by Blade Therapeutics. Prior to PharmAkea and ATXCo, Mr. Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which was acquired by Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. In addition to his executive leadership roles, Mr. Williamson has served as a Board member for privately held and publicly traded companies. Most notably, Mr. Williamson served as a member of the Board of Directors of Pharmasset, Inc., where he helped finance, grow, and advance the company to the public markets through its acquisition by Gilead in 2011 for $11 billion. He also served as a member of the Board of Directors of Progen Pharmaceuticals. Currently, Mr. Williamson serves as Chairman of HAYA Therapeutics SA and as a member of the Board of Directors of the Coulter Center in Miami.
Prior to his management roles in industry, Mr. Williamson was a partner with The Boston Consulting Group and was a research assistant for the Federal Reserve Board. He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford GSB.
Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.
Benjamin Kreitman broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.
Prior to joining Broadview, Benjamin was a Consultant at Monitor Deloitte, the strategy management consulting arm of Deloitte Consulting, LLP. At Monitor Deloitte, Benjamin worked alongside senior executives on a variety of engagements including commercial strategy development for biotechnology startups as well as global pharmaceutical and medical device manufacturers, and corporate development and investment due diligence across a number of industries.
Benjamin earned undergraduate degrees in Biological Sciences and Financial Economics Magna Cum Laude from Columbia University.
Daniel is a biotechnology scientist with 10 years’ experience working in the field of pharmaceutical biotech including various translational aspects of drug development and production. As a post-doctoral fellow at the Lausanne University Hospital (CHUV) Daniel worked on methods for therapeutic gene delivery and modulation using different modalities including antisense oligonucleotides. During his PhD at the University of Lausanne and Ecole Polytechnique Fédérale de Lausanne (EPFL), his work was focused on the development of novel strategies for manufacturing processes in compliance with GMP standards in support of different gene therapy applications and clinical trials.
Jens has more than 18 years of biopharma venture capital and company creation experience and 10 years of operational experience in drug discovery and development. Before joining Apollo Health Ventures as Managing Partner, Jens served as President of GlaxoSmithKline’s corporate venture fund SR One for eight years. Jens is also co-founder and was Managing Director of GSK’s Action Potential Venture Capital (APVC) fund which invests in pioneering bioelectronic technologies. Previously, Jens was a General Partner at TVM Capital leading early-stage investments in Boston.
Jens is a Kauffman Fellow, a member of the EU-sponsored Gold Track Expert Council, and a passionate mentor for entrepreneurs and start-up teams in the area of innovative life science and healthcare IT. Before his investment career, Jens was leading research teams and pharma collaborations at Enanta Pharmaceuticals (NASDAQ: ENTA) and Mitotix, Inc.